🇺🇸 US Stock Screener ← Switch market ⚡ HerAI

The Joint Corp. JYNT R2KPHARMA

Healthcare · Medical Care Facilities · United States
https://www.thejoint.com
Company Profile ↓
$7.20
-34.56% 1Y
Mkt Cap$101.83M
P/E51.43
P/B7.28
52W High$11.01
52W Low$6.90
Book Value$1.16
EPS (TTM)$0.14

Company Overview

The Joint Corp. operates and is a franchisor and operator of chiropractic clinics in the United States. The company provides services under the franchise agreement, including training of franchisees and staff, site selection, construction/vendor management and ongoing operations support. It operates through a network of franchised clinics, offering routine and affordable chiropractic adjustments using a private pay, non-insurance, cash-based model. The company was incorporated in 2010 and is headquartered in Scottsdale, Arizona.

Why Investors Should Care

Steady Revenue Expansion

Revenue has grown at a 20.3% CAGR over the past five years.

Conservative Balance Sheet

Carries low leverage with a debt-to-equity ratio of 0.13.

Positive Free Cash Flow

Generates positive free cash flow, funding growth and shareholder returns internally.

Recent Developments

  • Dec 2025 Revenue of $54.90M (+5.2% YoY).
  • Trailing 12 Months Year-on-year growth — revenue +14.4%, earnings +652.6%.
  • 5-Year Trend Long-term compounding — revenue CAGR 20.3%.

Growth & Price Performance

Compounded Sales Growth

5 Years:20.33%
1 Year:14.40%

Compounded Profit Growth

5 Years:-
1 Year:652.60%

Stock Price Performance

1 Year:-34.56%
6 Months:-20.12%
3 Months:-15.93%
1 Month:-13.09%

Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.

Technical Snapshot Bearish
52-Week Range 7% of range
$6.90 $11.01
Trend Signals
  • Price vs 50-DMABelow
  • Price vs 200-DMABelow
  • RSI (14)41.91 · Neutral
Price Performance
1M-13.09%
3M-15.93%
6M-20.12%
1Y-34.56%
Valuation vs Sector

P/E of 51.43 is above the sector median of 25.45 — pricier than peers.

Auto-generated from price history and fundamentals; not investment advice.

⚙Ad space

Price Chart

Robinhood TradingView

Fundamental Growth Charts

Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.

PROS

  • Compounding revenue at 20.3% over 5 years.
  • Generates positive free cash flow.

CONS

  • Trading at a high P/E of 51.4.
  • Trading 34.6% below its 52-week high.
  • In a downtrend (50-DMA below 200-DMA).

* The pros and cons are auto-generated from financial metrics.

⚙Ad space

Valuation

Stock P/E
51.43
Industry PE
25.45
Forward P/E
11.34
PEG Ratio
8.83
Book Value
$1.16
Price to Book
7.28
P/S
2.04
EV/EBITDA
23.56
Dividend Yield
0.00%

Growth (CAGR)

Revenue 5Y
20.33%
Profit 5Y
-
Revenue (YoY)
14.40%
Earnings (YoY)
652.60%

Profitability & Returns

ROCE
-3.24%
ROE
10.62%
ROA
2.33%
Profit Margin
6.49%
Op Margin
3.25%
Gross Margin
81.76%
EPS (Latest Qtr)
$0.05
EPS (TTM)
$0.14

Balance Sheet & Liquidity

Debt/Equity
0.13
Quick Ratio
1.02
Current Ratio
1.83
Debt
$2.04M
Total Assets
$51.63M
Current Assets
$49.59M
Working Capital
$19.27M

Ownership

Promoter Holding
16.23%
Chg in Prom Hold
0.13%
FII / Inst Holding
69.28%
Chg in FII Hold
-0.02%

Financial Snapshot

Enterprise Value
$101.83M
Total Revenue (TTM)
$58.55M
EBITDA
$4.02M
Free Cash Flow
$3.98M
Operating Cash Flow
$5.39M
Shares Outstanding
14.14M
Gross Margin
81.76%
Payout Ratio
0.00%

Peer comparison

Peer companies in the same sector (Healthcare).

#NameCMP $P/E Mkt CapDiv Yld % ROCE %ROE % Rev CAGR 5Y %Profit CAGR 5Y %
1 JYNT The Joint Corp. R2KPHARMA 7.20 51.43 $101.83M 0.00% -3.24% 10.62% 20.33% -
2 LLY Eli Lilly and Company SPXR3KPHARMA 1,273.46 42.83 $1.14T 0.60% - 102.29% 7.20% 11.41%
3 JNJ Johnson & Johnson SPXR3KPHARMA 263.81 30.60 $635.76B 1.98% 14.88% 25.74% 2.43% 4.76%
4 ABBV AbbVie Inc. SPXR3KPHARMA 285.64 80.69 $504.76B 2.54% 10.47% -129.24% 1.75% -29.06%
5 UNH UnitedHealth Group Incorporated SPXR3KPHARMA 418.09 26.85 $375.28B 2.47% 9.74% 14.15% 10.40% 5.43%
6 MRK Merck & Co., Inc. SPXR3KPHARMA 145.27 116.22 $358.41B 2.31% - 6.96% 5.64% 10.01%
7 NVS Novartis AG PHARMA 151.12 22.83 $287.24B 3.36% 21.09% 30.35% 9.25% 26.22%
8 AZN AstraZeneca PLC NDXPHARMA 171.49 25.63 $265.96B 2.00% 15.97% 21.96% 9.82% 45.96%
9 TMO Thermo Fisher Scientific Inc. SPXR3KPHARMA 673.82 36.30 $249.14B 0.29% 8.14% 13.51% 8.81% 12.95%
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios

Quarterly Results

Figures in USD.

Metric Jun 2014Sep 2014Mar 2015Jun 2015Sep 2015Mar 2016Jun 2016Sep 2016Mar 2017Jun 2017Sep 2017Mar 2018Jun 2018Sep 2018Mar 2019Jun 2019Sep 2019Mar 2020Jun 2020Sep 2020Mar 2021Jun 2021Sep 2021Mar 2022Jun 2022Sep 2022Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
Revenue 1.73M1.82M2.51M3.43M4.14M4.27M4.97M5.50M5.51M6.00M6.54M8.65M8.80M9.24M10.68M11.17M12.73M13.64M12.59M15.41M17.55M20.22M20.99M22.44M24.89M26.45M28.30M29.31M29.47M-29.72M30.26M30.20M-------
Operating Income -209.16K-310.82K-1.92M-1.85M-2.05M-3.48M-3.19M-2.62M-1.71M-995.53K-405.53K-83.78K-64.24K-247.04K943.67K487.60K640.38K753.35K258.58K1.71M1.97M2.03M1.34M-176.43K-1.33M732.32K-257.89K-414.64K-3.82K994.64K-426.60K-1.78M-492.82K809.72K-678.53K-1.14M160.91K742.41K873.67K-368.66K
Net Income -133.75K-202.37K-1.90M-1.86M-1.66M-3.53M-3.26M-2.63M-1.77M-1.02M-431.70K-31.61K-50.84K-207.54K952.64K462.26K616.98K814.95K115.58K1.60M2.31M2.68M1.94M-205.80K-871.87K731.10K2.33M-320.49K-716.27K-946.98K-3.60M-3.17M-------
Diluted EPS --0.04---------0.00--0.020.070.030.040.060.010.110.160.180.13-0.01-0.060.050.16-0.02-0.05-0.740.06-0.24-0.210.000.060.010.060.070.090.05

Profit & Loss (Annual)

Figures in USD.

Metric Dec 2013Dec 2014Dec 2015Dec 2016Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Revenue 5.96M7.12M13.84M20.52M24.92M36.66M48.45M58.68M80.86M101.25M117.70M52.16M54.90M
Operating Income 439.79K-1.63M-9.32M-15.01M-3.33M142.56K3.41M5.49M5.35M828.25K318.30K-1.89M-913.38K
Net Income 155.63K-3.03M-8.80M-15.17M-3.43M146.70K3.32M13.17M6.58M626.71K-9.75M--
Diluted EPS 0.02-0.56---0.260.010.230.900.440.04-0.65-0.380.19

Balance Sheet (Annual)

Figures in USD.

Metric Dec 2012Dec 2013Dec 2014Dec 2015Dec 2016Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Total Assets -9.77M28.47M33.36M17.05M18.44M23.43M43.71M65.88M-93.49M87.21M83.15M60.97M
Current Assets ----------17.61M44.34M74.58M52.09M
Cash & Equivalents 3.57M3.52M20.80M16.79M3.01M4.22M8.72M8.46M20.55M-9.75M18.15M25.05M23.60M
Inventory --------------
Receivables ----------3.91M2.58M2.59M2.85M
Total Liabilities -10.99M12.84M12.68M10.13M17.28M22.70M37.99M44.75M-60.90M62.44M62.48M45.89M
Current Liabilities -3.59M4.18M7.49M5.86M5.38M10.27M13.57M18.46M-23.22M33.57M49.04M32.82M
Long Term Debt ---581.85K331.50K100.00K---2.00M2.00M2.00M--
Total Debt ----------26.06M2.86M795.03K2.01M
Total Equity -1.14M-1.22M15.63M20.68M6.93M1.15M727.50K5.72M21.13M-32.56M24.75M20.65M15.05M
Shares Outstanding ----------14.56M14.78M15.19M15.47M

Cash Flows (Annual)

Figures in USD.

Metric Dec 2013Dec 2014Dec 2015Dec 2016Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Operating Cash Flow ----10.85M-74.13K5.45M7.52M11.18M-8.21M14.68M9.42M1.84M
Investing Cash Flow ----2.70M-372.85K-1.24M-7.14M-4.60M--17.90M-6.19M-631.55K6.27M
Financing Cash Flow ----239.85K1.42M326.30K-596.96K5.60M-328.61K174.12K-2.00M-9.81M
Capital Expenditure -241.41K-659.30K-4.07M-1.57M-449.20K-1.11M-3.48M-3.16M--5.90M-5.00M-1.19M-1.50M
Free Cash Flow ----12.42M-523.34K4.34M4.04M8.03M-2.31M9.68M8.23M334.72K
Net Change in Cash ----------9.36M8.66M6.78M-1.69M
Share Buybacks 240.00K--83.39K2.65K4.81K20.18K32.07K707.73K5.80K3.83K011.31M

Ratios (Annual)

Figures in %.

Metric Dec 2013Dec 2014Dec 2015Dec 2016Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Gross Margin % -------------
Operating Margin % 7.4%-22.9%-67.3%-73.1%-13.4%0.4%7.0%9.4%6.6%0.8%0.3%-3.6%-1.7%
Net Margin % 2.6%-42.6%-63.6%-73.9%-13.8%0.4%6.9%22.4%8.1%0.6%-8.3%--
ROE % -12.7%-19.4%-42.5%-219.1%-297.6%20.2%58.1%62.3%-1.9%-39.4%--
ROCE % 7.1%-6.7%-36.0%-134.1%-25.5%1.1%11.3%11.6%-1.2%0.6%-5.5%-3.2%

Shareholding Pattern

Insiders
16.23%
Institutions
69.28%
Public Float
82.70%

Top Institutional Holders

#Holder% HeldSharesValue
1 Bandera Partners LLC 27.84% 3.94M $27.72M
2 Skylands Capital, LLC 6.33% 895.57K $6.30M
3 JCP Investment Management, LLC 4.20% 593.91K $4.18M
4 Vanguard Capital Management LLC 3.94% 557.05K $3.92M
5 First Foundation Advisors 2.37% 334.87K $2.36M
6 Blackrock Inc. 2.04% 288.62K $2.03M
7 Russell Investments Group, Ltd. 2.02% 285.31K $2.01M
8 Jane Street Group, LLC 1.67% 235.85K $1.66M
9 Vanguard Portfolio Management LLC 1.59% 224.74K $1.58M
10 Renaissance Technologies, LLC 1.55% 219.48K $1.55M

Analyst View

Loading analyst coverage…

Latest News

Recent headlines for JYNT

Google News Fri, 23 Oct 2026

The Joint Corp. Estimates – NASDAQ:JYNT - TradingView

<a href="https://news.google.com/rss/articles/CBMieEFVX3lxTE5adTFzNTkzYmhRSGVTMGY0OUg3Sm1jSThYeUFoZTJLVjNzQVVkZzlwTEV1STBJeEFKdExyYkdfWE85aFpDVmpLdDF5Q0IydFF1akpKdWx5TTk4VEpDM2RfYlNNSktLZklRaTUzbWQxaFF0ekliMmpjMg?oc=5" target="_blank">The J…

Google News hu, 22 Oct 2026

The Joint Chiropractic has over 930 locations. It will report third-quarter results Nov. 5. - Stock Titan

<a href="https://news.google.com/rss/articles/CBMiugFBVV95cUxORU1zSlRIVnQ3OUw0VjRVLVU4NjhHRnBvOTU3dC1obTJaRHphSm1qeDVtM2g0VFJPT3U4ZkF3LXZwdnp3YlVGUEpPVjVWeVJoTnRBX0d5YUF0amxvN0M4NU5yTjA5eG8zUmJYLVpUMk5UT0FYYmhxSU1HdGZDR2xfQWMtUUt1R2htZ1FIbD…

Google News Fri, 23 Oct 2026

Responsive Playbooks and the JYNT Inflection - Stock Traders Daily

<a href="https://news.google.com/rss/articles/CBMiwgFBVV95cUxQRTVzNFR1MlM3MEVHWmw4cGU2eVd2SjE1SXpyY3daZXc3Nnk5SndfV3BzemtGOW1kbUIyM3dfSUdMbTM4SFJURk9peWJING1lLVozTHVrdHFpcDlOeE9RSnVBelRyX25NeGEyWkdwbVhQbkhSdjFGc0xXMVhHNDJ0X0tHdkRicHJSelZsOH…

Google News hu, 06 Aug 2026

The Joint Corp. (JYNT) Reports Q2 Loss, Tops Revenue Estimates - Yahoo Finance

<a href="https://news.google.com/rss/articles/CBMilgFBVV95cUxOcGVkY2FhUVpmNENzMVhUTko2YUM2NlhKVDVGRkFkemdQa3MzT0s0S0Z1VUNLbnhfUXVGa1V1YnJxMUR4VTdiV3N4Vm1pSTRGM2Yyb2d3cVV4RFNZYUd4d25scmlDY0ZHd245c3c3ZG0yQjNGVThEM19HX1IwSmpreVJEY3FNV2JmRlgwNT…

Google News ue, 26 May 2026

The Joint: Can Refranchising Unlock A Better Business? (NASDAQ:JYNT) - Seeking Alpha

<a href="https://news.google.com/rss/articles/CBMimAFBVV95cUxPdURSWmpiRElmdkY3NDRrQjR4ZWhxQlhOdXBYbEVTbzFRd1Q4b0FDSzh0dmR6a0hqQUtSdGpvUVJmUzQ3VERFNlowMHBBdzdUYVlQZUtnSDRXUWlRREh6djhZb0QwV01yNHgtbW9iSDJHcWFYUXotQ3VTdFBTWDhpTnRkOXlSTWtmYWNsR3…

Google News hu, 01 Oct 2026

What Does The Joint Corp.'s (NASDAQ:JYNT) Share Price Indicate? - Simply Wall Street

<a href="https://news.google.com/rss/articles/CBMiwwFBVV95cUxPd0VuSkJ6OThzSFRVWnJTVldIZi1WN3ZsOUdDNlBlRGxkU0VYNXBvWTVZNXl2LWxFUjZkczJ6SWVaMzVWVDVtZUpqaFZIcnA0cjB4VlE0TGt6VDloV2RWMVM1eVQ0VEg4UXJJN0ZVWkpOemhQQUcwMGU1UkhkM0N5WVQwTnBnWDlCeE43an…

JYNT — Frequently Asked Questions

What is the current share price of The Joint Corp. (JYNT)?

As of 2026-10-23 16:27 PDT, The Joint Corp. (JYNT) trades at $7.20 on NasdaqCM. Its 52-week range is $6.90 to $11.01.

What is the market capitalisation of JYNT?

The Joint Corp. (JYNT) has a market capitalisation of $101.83M on NasdaqCM.

What is the P/E ratio of JYNT?

JYNT trades at a trailing price-to-earnings (P/E) ratio of 51.43. The industry average P/E is 25.45. Its price-to-book (P/B) ratio is 7.28.

What is the return on equity (ROE) of JYNT?

JYNT has a return on equity (ROE) of 10.62%. Its return on capital employed (ROCE) is -3.24%.

Is JYNT a good stock to buy?

This page provides a data-driven analysis of The Joint Corp. (JYNT), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.

Explore More

📊 Healthcare Sector 🔍 All Stock Screens 📈 Technical Screens 💰 Fundamental Screens 🔄 Swing Trading Setups 📐 Chart Patterns 📅 Earnings Calendar 📋 All USA Stocks
⚙Ad space